In early postmenopausal women, zoledronate vs. placebo at baseline and 5 y reduced morphometric vertebral fractures at 10 y

GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text] Geriatrics: [Formula: see text] Public Health: [Formula: see text].